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Until the twilight of the 20th century, genetics was
a branch of medicine applied to diseases of rare
occurrence.  The advent of the human genome sequence
and the possibility of studying it at affordable costs for
patients and healthcare institutions, has permitted its
application in high-priority diseases like cancer,
cardiovascular disease, diabetes, and Alzheimer’s,
among others.
There is great potential in predictive and preventive
medicine, through studying polymorphic genetic
variants associated to risks for different diseases.
Currently, clinical laboratories offer studies of over
30,000 variants associated with susceptibilities, to
which individuals can access without much difficulty
because a medical prescription is not required. These
exams permit conducting a specific plan of preventive
medicine.  For example, upon the possibility of finding
a deleterious mutation in the BRCA1 and BRCA2
genes, the patient can prevent the breast cancer by
mastectomy or chemoprophylaxis and in the presence
of polymorphisms associated to cardiovascular risk
preventive action may be undertaken through changes
in life style (diet, exercise, etc.).
Legal aspects are also present in this new conception
of medicine.  For example, currently there is legislation
for medications to indicate on their labels the different
responses such medication can offer regarding the
genetic variants of the patients, given that similar doses
may provoke adverse reactions in an individual, while
for another such dosage may be insufficient. This
scenario would allow verifying the polymorphisms of
drug response prior to administering medications like
anticoagulants, hyperlipidemia treatments, or
chemotherapy, among others.
We must specially mention recessive diseases,
produced by the presence of two alleles of a mutated
gene, which are inherited from the mother, as well as
the father. By studying the mutations, we may learn if
a couple is at risk of bearing children with the disease;
thus, conducts may be undertaken like selection of
embryos or opting for adoption.
Although genetic studies of molecular profiles are
promissory, there are questions on how these are
requested and how the results are communicated to the
patients, their clinical use, application of the pre-
symptomatic diagnosis – especially in children, the bad
intended use of this information by medical insurance
companies considering pre-existing conditions, and
finally, the great amount of information and its
application in populations where prior studies of
association have not been conducted may be cause for
concern.
In developed nations, these types of exams are
requested without medical prescription in pharmacies
that mail the results directly to the interested party.  It
is worrisome what can happen to patients upon receiving
this information; for example, if the report indicates
susceptibility to Alzheimer’s or cancer, without medical
support to identify the presentation risks and the
possibility of transmitting the disease to their offspring.
This suggests the validity, more than ever, of genetic
counseling when delivering analysis results.
On the other hand, insurance companies must
consider molecular genetic profiles as a preventive tool
that permits improving service quality while lowering
costs; for instance, in cancer cases where prophylaxis
measures are notably less costly than treatment.
Another aspect to bear in mind is that association
studies of genetic polymorphism and disease need
thousands of cases and controls, making them very
costly for implementation in Colombia. For this reason,
the exams include the ancestral report for the purpose
of interpreting the results according to ethnic origin.
For now, this is the most adequate conduct considering
that it will take a long time before validation studies can
be conducted.
As with all great progress in medicine, genomics
opens a path that will bring enormous benefit inasmuch
as the criteria for good medical practices are considered.
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